Feb 7, 2026
Which patient subgroups (tau burden, APOE4 status, clinical stage) show the largest benefit from donanemab or lecanemab in trial subgroup analyses?
shows its clearest, largest subgroup benefit in patients with low-to-medium baseline burden (the “earlier” tau stage), with subgroup analyses reporting roughly one-third slower clinical decline and hi...